GlassScriptPhysician profile
Jennifer White
NPI 1982103784
$1,710.12
in general payments reported to CMS, 2019-2025
33 companies · $60.58 in 2025
The $60.58 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,418 · 2022: $109 · 2023: $83.64 · 2024: $38.92 · 2025: $60.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $213.70 | 2021-2024 | Imfinzi, Tagrisso |
| Seagen INC. | $154.22 | 2021-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $134.64 | 2021 | |
| Eisai INC. | $116.02 | 2021 | |
| Amgen INC. | $109.25 | 2021-2022 | |
| Janssen Biotech, INC. | $98.24 | 2021 | |
| Genzyme Corporation | $81.76 | 2021 | |
| Epizyme, INC. | $79.98 | 2021-2022 | |
| Abbvie INC. | $71.94 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $66.96 | 2021 | |
| Daiichi Sankyo INC. | $66.04 | 2021 | |
| Celgene Corporation | $46.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.25 | 2021 | |
| Kite Pharma, INC. | $37.45 | 2021 | |
| Merck Sharp & Dohme LLC | $36.42 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.58 | 2021 | |
| Glaxosmithkline, LLC. | $30.94 | 2021 | |
| Taiho Oncology, INC. | $30.62 | 2021 | |
| Pfizer INC. | $29.72 | 2021 | |
| Amag Pharmaceuticals, INC. | $26.98 | 2021 | |
| Adaptive Biotechnologies Corporation | $19.65 | 2021 | |
| Ionis Pharmaceuticals, INC. | $18.75 | 2025 | Dawnzera |
| Genentech USA, INC. | $18.28 | 2021 | |
| Abbott Laboratories | $17.94 | 2021 | |
| Exelixis INC. | $16.21 | 2021 | |
| Gilead Sciences, INC. | $15.92 | 2021 | |
| Incyte Corporation | $15.63 | 2021 | |
| Beigene USA, INC. | $15.37 | 2021 | |
| Acceleron Pharma, INC. | $15.27 | 2021 | |
| Rigel Pharmaceuticals, INC. | $14.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.45 | 2021 | |
| Array Biopharma INC | $12.55 | 2021 | |
| Genmab U.S., INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.